VBI VACCINES INC. (TSE:VBV) Files An 8-K Other Events
Item 8.01 Other Events.
On December 18, 2018, VBI Vaccines Inc. issued a press release announcing closing of its previously announced underwritten public offering of common shares and partial exercise of underwriters’ option to purchase additional common shares for aggregate gross proceeds of $42.9 million. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description |
| 99.1 | Press Release dated December 18, 2018 |
VBI Vaccines Inc/BC Exhibit
EX-99.1 2 ex99-1.htm VBI Vaccines Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriter’s Option to Purchase Additional Shares for Aggregate Gross Proceeds of $42.9 Million CAMBRIDGE,…
To view the full exhibit click here
About VBI VACCINES INC. (TSE:VBV)
VBI Vaccines Inc. is a development-stage biotechnology company. The Company’s principal products include cytomegalovirus (CMV) Vaccine Candidate, enveloped Virus Like Particle (eVLP) Vaccine Platform and Lipid Particle Vaccine (LPV) Vaccine Platform. The Company is also engaged in the research and development (R and D) activity. The Company’s subsidiaries includes Variation Biotechnologies (US), Inc. (VBI US) and Variation Biotechnologies Inc. (VBI Cda).